[{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"8e72eb1e-e98c-4dc8-902a-51141f27ce4b","acronym":"ELIANA","url":"https://clinicaltrials.gov/study/NCT02435849","created_at":"2021-01-18T11:39:44.133Z","updated_at":"2024-07-02T16:35:19.600Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients","source_id_and_acronym":"NCT02435849 - ELIANA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19 • TCF3","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 01/21/2020","primary_completion_date":" 01/21/2020","study_txt":" Completion: 11/17/2022","study_completion_date":" 11/17/2022","last_update_posted":"2024-02-13"},{"id":"846c7816-a265-4367-9445-7a5279012747","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236857","created_at":"2021-01-18T15:59:38.618Z","updated_at":"2024-07-02T16:35:47.459Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","source_id_and_acronym":"NCT03236857","lead_sponsor":"AbbVie","biomarkers":" BCL2 • TCF3","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 04/19/2023","primary_completion_date":" 04/19/2023","study_txt":" Completion: 04/19/2023","study_completion_date":" 04/19/2023","last_update_posted":"2023-05-22"},{"id":"bbe59d28-d934-4e00-a784-01daf74e8e90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05576181","created_at":"2022-10-12T13:56:47.128Z","updated_at":"2024-07-02T16:36:02.594Z","phase":"Phase 1","brief_title":"Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05576181","lead_sponsor":"Fundamenta Therapeutics, Ltd.","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/15/2022","start_date":" 10/15/2022","primary_txt":" Primary completion: 01/22/2025","primary_completion_date":" 01/22/2025","study_txt":" Completion: 07/22/2025","study_completion_date":" 07/22/2025","last_update_posted":"2022-10-12"},{"id":"fbe744f1-4127-4b91-9548-593e8806c892","acronym":"FT400-004","url":"https://clinicaltrials.gov/study/NCT05350787","created_at":"2022-04-28T17:56:11.330Z","updated_at":"2024-07-02T16:36:11.294Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL","source_id_and_acronym":"NCT05350787 - FT400-004","lead_sponsor":"Zhejiang University","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IFNG • IL6 • IKZF1 • TNFA • JAK1 • IL2 • IL7R • IL10 • TCF3 • TGFB1 • IL17A • SH2B3 • IL1B","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IFNG • IL6 • IKZF1 • TNFA • JAK1 • IL2 • IL7R • IL10 • TCF3 • TGFB1 • IL17A • SH2B3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2022-04-28"},{"id":"13a6378f-892e-4f0d-8c8d-47b7eaa35728","acronym":"ALaCART","url":"https://clinicaltrials.gov/study/NCT05038696","created_at":"2021-09-09T13:53:04.247Z","updated_at":"2024-07-02T16:36:24.664Z","phase":"Phase 1","brief_title":"ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.","source_id_and_acronym":"NCT05038696 - ALaCART","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ABL1 • BCR • CD19 • PDGFRB • TCF3","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • CD19 • PDGFRB • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2021-09-09"},{"id":"08d3cf7e-53db-4d97-bd5c-e37278f8ab16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04787263","created_at":"2021-03-08T12:53:53.051Z","updated_at":"2024-07-02T16:36:32.763Z","phase":"Phase 1/2","brief_title":"CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML","source_id_and_acronym":"NCT04787263","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" TP53 • CD19 • TCF3 • PBX1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD19 expression","tags":["TP53 • CD19 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-CAR_Lenti T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2038","study_completion_date":" 03/03/2038","last_update_posted":"2021-03-26"}]